Chemotherapy and its evolving role in the management of advanced prostate cancer
Advanced prostate cancer has been recognized as being responsive to androgen deprivation since the 1940s when Charles Huggins first described the role of surgical castration in managing these patients. However, androgen deprivation only results in transient disease control for the vast majority of m...
Main Authors: | Michael T Schweizer, Emmanuel S Antonarakis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-06-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=334;epage=340;aulast=Schweizer |
Similar Items
-
TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01) -
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
by: Tomas Buchler, et al.
Published: (2007-01-01) -
The role of taxanes in prostate cancer: literature review
by: A. K. Norsov, et al.
Published: (2018-07-01) -
Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells
by: Oblad, Richard Vernon
Published: (2018) -
Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Johann de Bono, et al.
Published: (2016-03-01)